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Background: The measurement of monoclonal free light chains is being increasingly 
utilised since the introduction of serum based assays. It is important for laboratories to 
determine their own reference ranges in order to reflect the local population. The aim of this 
study was to determine if age-adjusted reference ranges for serum free light chains would 
have implications for demand management of further laboratory investigations including 
immunofixation. 
Methods: After certain exclusions, 4293 samples from individuals seen in primary care 
across Oxfordshire between 2014–2016 were identified for analysis of patient 
characteristics, serum free light chain results and estimated glomerular filtration rate.  
Results: We found age to be an independent variable when considering serum free light 
chain concentrations, ratio and estimated glomerular filtration rate. The reference ranges 
derived from our data differ markedly from the original Binding Site ranges. When the age-
specific ranges are retrospectively applied to our population there is a 38% decrease in 
follow up testing with no loss of specificity.    
Conclusion: We feel confident implementing new age-specific serum free light chain 
reference ranges in our laboratory. We have developed a simple algorithm for evaluating 
serum free light chains based on age and estimated glomerular filtration rate.  We 
encourage laboratories to establish their own local reference ranges using large cohorts and 
their chosen serum free light chain assay platform.  
  
Background 
The detection of monoclonal free light chains has historically been performed by urine 
electrophoresis, conducted alongside the serum investigations. Obtaining urine samples for 
immunological investigations from patients is challenging; studies from both primary and 
secondary care have shown that, at best, only 40% of patients have urine electrophoresis 
performed and in some studies, this is as low as 5%.1, 2 
Serum free light chain (FLC) assays allow the identification and quantification of kappa and 
lambda immunoglobulin FLCs and indirect determination of monoclonality using the 
kappa:lambda ratio (FLCr).3 Novel disease classifications have arisen using these methods 
including light chain MGUS, defined by the absence of paraprotein by serum protein 
electrophoresis (SPEP) and serum immunofixation (IFE) and presence of abnormal FLCr 
and raised FLC concentrations.4  
In 2016, the NICE guidelines for myeloma diagnosis and management recommended the 
introduction of FLC measurement (alongside SPEP) into the myeloma diagnostic algorithm, 
“to confirm the presence of a paraprotein indicating possible myeloma or monoclonal 
gammopathy of undetermined significance (MGUS)”.5 These guidelines also recommend 
performing IFE on all samples with abnormal FLCr. Both recommendations highlight the 
importance of having accurate reference ranges which reflect the population being tested. 
The 2009 International Myeloma Working Group (IMWG) guidelines recommend treating 
myeloma patients with LC ratio of >100 in the absence of other CRAB features 
(hypercalcaemia, renal failure, anaemia, and bone lesions) due to increased risk of 
progression to active myeloma.6 
Accordingly, FLC measurements are now the standard of care for patients with plasma cell 
dyscrasias. In primary care the FLC assay can aid decision making regarding further 
laboratory investigations, including IFE, and onward referral to secondary care. In secondary 
care, FLC measurement can aid the diagnosis, prognostication and on-going management 
of patients with plasma cell dyscrasias.   
The Freelite (The Binding Site, UK) assay is a turbidimetric assay which uses polyclonal 
antibodies directed at epitopes of the FLC constant region which are hidden in intact 
immunoglobulins; therefore only light chains which are unbound to a heavy chain are 
quantified. The reference range supplied by The Binding Site (Birmingham, UK) for FLCr is 
0.26-1.65 (kappa concentration: 3.30-19.40mg/L, lambda concentration: 5.71-26.30mg/L 
using the 95th percentile). This data was obtained from a limited number of samples (282 
normal subjects aged 20 to 90 years) and was intended for guidance purpose only.7 The 
FLCr range supplied by The Binding Site is used in the IMWG diagnostic criteria for light-
chain MGUS and therefore has an impact on both the diagnosis and monitoring of this 
disorder. 8 
The aim of this study was to generate age-adjusted reference ranges for FLC and FLCr. As 
serum FLC concentrations are known to be affected by GFR, we also took the eGFR values 
of our cohort under consideration. By retrospectively applying the novel reference ranges to 
the overall cohort, we demonstrate our approach has significant implications for demand 




A service evaluation of laboratory diagnostics at the Immunology Laboratory, Oxford, was 
undertaken to evaluate the clinical utility and cost-effectiveness of screening for plasma cell 
dyscrasias in 4544 consecutive serum samples sent for serum protein electrophoresis from 
individuals seen in primary care across Oxfordshire, UK in 2014-2016.  
Patients enrolled in this study were >20 years of age with no known prior history of 
lymphoproliferative disease, confirmed by the Laboratory Information Management System 
(LIMS). All samples underwent nephelometric immunoglobulin measurement (Architect 
C4000, Abbott) and SPEP (V8, Helena) within 3 days of receipt in the laboratory. 
Measurement of FLC concentrations using the SPAPlus analyser (The Binding Site, UK) and 
Binding Site reagents was performed within 21 days of receipt in the laboratory. This data 
set was used to validate the Freelite reference range provided by the Binding Site and to 
generate age specific reference ranges for FLC and FLCr.   
The following exclusions were made: 26 samples (0.6%) were excluded because clinical 
details provided on the request card included chronic kidney disease (CKD); 204 (4.5%) 
patients were excluded because a monoclonal protein was identified on SPEP; all patients 
with a FLCr outside of the established Binding Site normal range underwent immunofixation 
(Hydrasys, Sebia) which identified a monoclonal protein in a further 21 (0.5%) patients who 
were also excluded.  
Results from the remaining 4293 samples were taken forward for further analysis. Samples 
were stratified by age into four groups: 20-40 (445 patients), 41-60 (1151 patients), 61-80 
(1972 patients), 81+ (725 patients). Each age group was subject to normality plotting of 
kappa and lambda light chain concentrations and FLCr (Analyse-it for Microsoft Excel, 
Version 2.20, Analyse-it Software, Ltd) to dismiss samples that could represent patients with 
significant disease. The normally distributed region of each group was then selected and a 
2.5th-97.5th percentile analysis carried out to define normal ranges for serum free kappa and 
lambda concentrations and FLCr.  
Figure 1 shows an example of the Normal Q-Q plot for kappa light chain concentrations in 
the 20-40 age group. As renal impairment can significantly affect FLC concentrations, eGFR 
values were calculated based on serum creatinine assayed within 3 months of the FLC 
samples, utilising the ‘Modification of Diet in Renal Disease (MDRD)’-formula. 9 
One-way ANOVA analysis was carried out for the four variables (kappa concentration, 
lambda concentration, FLCr and eGFR) between the four age groups. A P-value of <0.05 
was considered significant. 
 






The median age within the cohort was 67 years (range 20-102), with 59% of the samples 
originating from females. When modelling the data, both Age vs FLCr (r = 0.29, P<0.001, 
95% CI [0.27, 0.32]) and eGFR vs FLCr (r = -0.24, P<0.001, 95% CI [-0.27, -0.22]) 
relationships were found to be linear. 
 
Table 1 shows the range of free kappa concentration, free lambda concentration, FLCr and 
eGFR generated from the entire cohort with 2.5th-97.5th percentile analysis performed prior 
to normality plotting.  
 
Table 1. Free light chain concentration and ratio by age range for the entire cohort prior to 











20-40 445 5.0 – 23.0 5.3 – 27.2 0.46 – 1.55 39 - >90 
41-60 1151 5.4 – 29.0 5.5 – 28.9 0.50 – 1.95 34 - >90 
61-80 1972 6.4 – 43.6 6.0 – 36.0 0.60 – 2.0 25 - >90 
81+ 725 8.6 – 60.8 6.7 – 47.8 0.67 – 2.4 21 - >90 
 
n = number of individuals 
 
 
Table 2 shows the range of free kappa concentration, free lambda concentration, FLCr and 
eGFR generated from the normally distributed cohort, following normality plotting with the 
2.5th-97.5th percentile analysis performed. The data presented in Table 2 represent the 
normal reference ranges we consider to be useful and have adopted in clinical practice.  
 
Table 2. Free light chain concentrations, free light chain ratio and eGFR by age range for 



















20-40 7.5 – 16.8 328 9.1 – 20.2 305 0.73 – 1.48 293 63 - >90 407 
41-60 9.6 – 21.6 725 9.8 – 22.6 750 0.87 – 1.45 678 58 - >90 1079 
61-80 11.3 – 27.6 1238 10.3 – 24.4 1307 0.99 – 1.80 1260 40 - >90 1864 
81+ 14.2 – 37.0 451 13.7 – 38.0 448 1.0 – 1.80 480 27 - >90 709 
 
n = number of individuals 
 
Using the normally distributed data in Table 2, one way ANOVA analysis of the different age 
groups reveals significant differences between each age group (P<0.001) for all variables 
(kappa concentration, lambda concentration, FLCr and eGFR). No statistically significant 
relationship was observed between gender and any of the variables.  
 
Figure 2 shows the prevalence data for eGFR ranges within each age group after normality 
plotting and 2.5th-97.5th percentile analysis. A normal eGFR is considered to be 
≥60ml/min/1.73m2. The prevalence of eGFRs within CKD classifications 3-4 (which are 
classified by progressively worsening renal impairment starting as eGFR <60ml/min/1.73m2) 
increased with age, however no patients in the cohort had an eGFR within the CKD 5 range 
(<15ml/min/1.73m2). This is likely to reflect the fact that these patients are principally 
managed in secondary, not primary care. None of the patients with eGFR <60ml/min/1.73m2 
can be classified as having CKD without other markers of kidney disease being present. The 
eGFR prevalence by age results from our analysis are concordant with those found by a 
large retrospective study calculating eGFR in primary care patients from Oxfordshire.10 
 
[Insert Figure 2 and legend] 
 
The 2016 NICE guidelines recommend performing serum IFE on any patients with an 
abnormal SPEP or FLCr. 5 We retrospectively applied the new normally distributed FLCr and 
eGFR ranges to the data. Based on the Binding Site FLCr ranges, 410 patients underwent 
serum IFE. Using our new reference ranges 254 patients would have undergone serum IFE, 
representing a 38% reduction. The new reference ranges would have failed to identify four 
patients with small paraproteins only identified by serum IFE. Two year follow up of these 
patients shows no evidence of a persistent monoclonal gammopathy, suggesting these 
paraproteins were transient, reactive phenomena.  
Conclusion 
The establishment of normal reference ranges is essential to allow the meaningful 
interpretation of laboratory investigations. We measured FLC in over 4000 primary care 
patients sent for immunoglobulin testing using the Binding Site Freelite platform. We 
demonstrate significantly different normal reference ranges for serum free kappa 
concentration, serum free lambda concentration and the kappa/lambda ratio based on an 
individual’s age. This contrasts with previous smaller studies that found age was not an 
independent variable when considering serum free light chain concentrations.3, 11 Both of 
these studies enrolled less than 150 patients and were likely underpowered to identify such 
differences 
In our population renal impairment consistent with CKD stages 3-5 increased with age, as 
previously show.12 The eGFR age-specific ranges produced by our data concur with age-
specific values produced from over 3500 non-diseased Caucasian participants in the 
Netherlands.12 As accurate classification of CKD stages 3-5 requires decreased eGFR 
values over a minimum period of 3 months we are unable to determine the true prevalence 
of CKD within the study population. Nevertheless, we did determine a weak inverse 
association between renal function as assessed by eGFR and serum free light chain ratio. 
This is in concordance with previous work assessing FLC in patients with CKD but without 
monoclonal gammopathy.9 It was found that these patients had higher FLCr when compared 
to the original healthy volunteer range. From this work on patients in renal failure a new 
‘normal’ FLCr range (0.37-3.1) was  proposed for patients with renal impairment, regardless 
of age, and is currently in use in our laboratory.9, 13  
The National Kidney Foundation (NKF) recommends a cut-off of 60ml/min/1.73m2 or below 
to categorise a patient as having CKD.14 However, the CKD classification guidelines 
produced by the NKF make no distinction based on either age or gender. The MDRD 
equation used to calculate eGFR was developed using nephrology referral patients with 
elevated serum creatinine levels 15; however, it has been found to have a more limited use 
for the general population, underestimating GFR in healthy subjects.16  
It has been shown a number of times that GFR declines with normal aging 12, 17, with a 
decline of approximately 5-10ml/min per decade; this compares well with our data. The 
study in the Netherlands showed that defining a cut-off for CKD without taking age into 
account can lead to misclassification, with a significant minority of mostly older healthy 
subjects, having an eGFR below 60 ml/min/1.73m2. 12 Many of the patients in our cohort who 
are >60 years of age would meet the NKF criteria for moderate CKD and our data show that 
an eGFR of 60 ml/min/1.73m2 is within the normal reference range for patients aged 41 
years and over.   
It has previously been established that eGFR values <60ml/min/1.73m2 are associated with 
a worse prognosis and that in the general population overall mortality risk is significantly 
increased below this cut off. 14, 18 A large cohort study however found that, although present, 
this association between eGFR of <60ml/min/1.73m2 and mortality was far weaker in elderly 
subjects than in the younger age groups. 19 This study found that an eGFR of 50-
59ml/min/1.73m2 was associated with increased mortality in subjects aged 18-54 years. This 
compares well with our lower limit of the eGFR normal range for <60 year olds being 
58ml/min/1.73m2. From the extensive data, this study suggested that mortality risk 
stratification should not be based on the same eGFR cut-off points for all ages, and 
proposed an eGFR cut-off between 30-59ml/min/1.73m2 for elderly patients.  This also 
compares well with our data for both the 61-80 years and 81+ years age groups and the 
data produced in the Netherlands study. 12  
Within our primary care population, we hypothesise that a decline in renal function and an 
increase in subclinical non-renal illnesses with age will contribute to the increased FLC 
ranges seen in this study and this will not lead to false normal results. To ensure this we 
performed a two year follow up on all patients through laboratory records, and found no 
patients with FLCr within the new normal ranges had developed a plasma cell dyscrasia.  
As we have used a primary care population, rather than a healthy control population to 
calculate these ranges it is possible that patients with non-renal illnesses can have raised 
FLC concentrations. However these raised concentrations have so far been seen to either 
not affect FLCr or result in only a borderline increased FLCr.20-22 
Our ranges varied from those stated in the Binding Site kit insert and have time and cost 
implications for the laboratory, as shown by the reduction of serum IFEs needing to be 
performed. For our data set, this reduction is exclusively due to the adjustment of the FLCr 
ranges for our different age groups. Notably, FLC assays have been shown to be platform 
dependent 23 and so these ranges can only apply to samples being tested on the SPAPlus 
analyser using the Binding Site reagents. We generated this data using a primary care 
population as a substitute for a large healthy control population. We believe that these 
ranges can also be applied to patients in secondary care being screened for monoclonal 
gammopathies, with renal impairment being taken into account. A study in tertiary care 
samples found a high false positive FLCr rate in those without a monoclonal gammopathy 
when using the original Binding Site FLC reference ranges.24 This supports the data we 
have found in our primary care population and suggests that our alternative ranges can be 
applied across the different care cohorts. We encourage laboratories to establish their own 
local reference ranges using large cohorts and their chosen FLC platform.  
With our follow up indicating no missed plasma cell dyscrasia patients, we can be confident 
in implementing these ranges into our routine practice with the aim to reduce the number of 
unnecessary follow up tests and referrals for patients being screened with SPEP and FLC in 
line with the 2016 NICE guidelines.5 From both our data analysis and previous data we feel 
age-specific eGFR values should be used when screening patients for monoclonal 
gammopathy. We feel confident in setting new eGFR cut-off limits, below which to use the 
previously calculated FLCr renal reference range. 9, 13 These cut-offs remain at 
<60ml/min/1.73m2 for patients aged 60 years and below, but decrease to <40ml/min/1.73m2 
for patients aged 61 years and over.  
Accordingly, we have developed an algorithm for interpreting FLC results and determining 
whether further investigation with IFE is warranted in the presence of a normal SPEP. If a 
patient has significant renal dysfunction as defined by the eGFR cut-off for their age 
(<60ml/min/1.73m2 for patients aged 60 years and below, <40ml/min/1.73m2 for patients 
aged 61 years and over) then the previously generated renal FLCr reference range (0.37-
3.1) will be used for interpretation. 
If eGFR is >60ml/min/1.73m2 for patients aged 60 years and below, or >40ml/min/1.73m2 for 
patients aged 61 years and over, then the age adjusted ranges calculated from patients 
where significant renal dysfunction had been excluded will be used (Table 2). This should 
reduce patients inappropriately being labelled as light-chain MGUS, reduce the need for 
long-term follow up and monitoring, and reduce the burden of further laboratory investigation 






1. Hill PG, Forsyth JM, Rai B and Mayne S. Serum free light chains: an alternative to the urine 
Bence Jones proteins screening test for monoclonal gammopathies. Clinical chemistry. 2006; 52: 
1743-8. 
2. Robson E, Taylor J, Beardsmore C, Basu S, Mead G and Lovatt T. Utility of Serum Free Light 
Chain Analysis When Screening for Lymphoproliferative Disorders: The Experience at a District 
General Hospital in the United Kingdom. Labmedicine. 2009; 40: 325-9. 
3. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for 
immunoglobulin free light chains in serum and urine. Clinical chemistry. 2001; 47: 673-80. 
4. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain 
monoclonal gammopathy of undetermined significance: a retrospective population-based cohort 
study. Lancet (London, England). 2010; 375: 1721-8. 
5. NICE. Myeloma: diagnosis and management. NICE Guideline. 2016; NG35. 
6. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for 
serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009; 23: 215-
24. 
7. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges 
for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of 
monoclonal light chains. Clinical chemistry. 2002; 48: 1437-44. 
8. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group 
updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014; 15: e538-48. 
9. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary 
polyclonal free light chains in patients with chronic kidney disease. Clinical journal of the American 
Society of Nephrology : CJASN. 2008; 3: 1684-90. 
10. Callaghan CA, Shine B and Lasserson DS. Chronic kidney disease: a large-scale population-
based study of the effects of introducing the CKD-EPI formula for eGFR reporting. BMJ Open. 2011; 
1: e000308. 
11. Galvani L, Flanagan J, Sargazi M and Neithercut WD. Validation of serum free light chain 
reference ranges in primary care. Annals of clinical biochemistry. 2016; 53: 399-404. 
12. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL and den Heijer M. Age- and gender-
specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney 
international. 2007; 72: 632-7. 
13. Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the 
diagnosis of myeloma in patients with severe renal failure. BMC nephrology. 2008; 9: 11. 
14. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic 
kidney disease: a KDIGO Controversies Conference report. Kidney international. 2011; 80: 17-28. 
15. Kusek JW, Coyne T, de Velasco A, et al. Recruitment experience in the full-scale phase of the 
Modification of Diet in Renal Disease Study. Controlled clinical trials. 1993; 14: 538-57. 
16. Poggio ED, Wang X, Greene T, Van Lente F and Hall PM. Performance of the modification of 
diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic 
kidney disease. Journal of the American Society of Nephrology : JASN. 2005; 16: 459-66. 
17. Rule AD, Gussak HM, Pond GR, et al. Measured and estimated GFR in healthy potential 
kidney donors. American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2004; 43: 112-9. 
18. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration 
rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a 
collaborative meta-analysis. Lancet (London, England). 2010; 375: 2073-81. 
19. O'Hare AM, Bertenthal D, Covinsky KE, et al. Mortality risk stratification in chronic kidney 
disease: one size for all ages? Journal of the American Society of Nephrology : JASN. 2006; 17: 846-
53. 
20. Redegeld FA, Thio M and Groot Kormelink T. Polyclonal immunoglobulin free light chain and 
chronic inflammation. Mayo Clinic proceedings. 2012; 87: 1032-3. 
21. Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light 
chains to predict overall survival in the general population. Mayo Clin Proc. 2012; 87: 517-23. 
22. Piehler AP, Gulbrandsen N, Kierulf P and Urdal P. Quantitation of serum free light chains in 
combination with protein electrophoresis and clinical information for diagnosing multiple myeloma 
in a general hospital population. Clinical chemistry. 2008; 54: 1823-30. 
23. Lock RJ, Saleem R, Roberts EG, et al. A multicentre study comparing two methods for serum 
free light chain analysis. Annals of clinical biochemistry. 2013; 50: 255-61. 
24. Singh G. Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without 
Monoclonal Gammopathies:  High False-Positive Rate. American Journal of Clinical Pathology. 2016; 
146: 207-14. 
